TRIM59通过通过RING域调节炎性细胞因子来缓解急性呼吸困扰综合征
Zheng Jin1, Xiaopeng Jing2, Ji Zeng2
1Department of Clinical Laboratory, Wuhan Fourth Hospital, Wuhan, China; Department of Respirology & Allergy, Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
Immunobiology
|September 23, 2025
概括
这项研究发现,TRIM59通过调节巨细胞来预防急性呼吸困扰综合征 (ARDS). 这一发现凸显了TRIM59作为ARDS治疗的潜在治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 病理学 病理学 病理学
背景情况:
- 急性呼吸困扰综合征 (ARDS) 呈现出显著的发病率和死亡率,自COVID-19以来,复杂性增加.
- 膜巨细胞 (AMs) 在先天免疫和免疫调节中至关重要,在ARDS病原和细胞因子风暴中发挥关键作用.
- 一个巨细胞表达的分子TRIM59在ARDS发病过程中的确切作用需要进一步阐明.
研究的目的:
- 研究TRIM59在ARDS病变和进展中的作用.
- 为了确定TRIM59是否对ARDS有保护作用.
- 阐明TRIM59影响ARDS的潜在机制.
主要方法:
- 建立了ARDS的动物模型,使用TRIM59在骨髓衍生巨细胞 (BMDMs) 中特别淘汰的小鼠.
- 研究了TRIM59对ARDS的体内保护作用.
- 进行了机制研究,以探索TRIM59对巨细胞功能和信号通路的影响.
主要成果:
- 在体内,TRIM59显示出对ARDS的保护作用.
- TRIM59的保护作用是通过其对巨细胞的调节来调节的.
- 机械分析显示,TRIM59通过其RING域抑制核因子-κB (NF-κB) 信号通路.
结论:
- 在ARDS中,TRIM59起到关键的调节分子作用.
- TRIM59对巨细胞功能的调节和NF-κB通路的抑制有助于缓解ARDS.
- TRIM59代表了ARDS治疗的潜在新型治疗点.
相关概念视频
01:29Acute Respiratory Failure-V
466
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
466
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.1K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.1K
01:28Inflammatory Response
16.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
16.0K
01:05Breathing
64.2K
The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
64.2K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.8K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.8K
01:21Acute Respiratory Failure-II
1.0K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.0K